Spinogenix is using small molecule drugs to regenerate synapses in patients with ALS, Alzheimer's disease, schizophrenia, ...

New research provides evidence that synaptic NMDAR number and subunit composition are not static, but change dynamically in a cell- and synapse-specific manner during development and in response ...

Our research supports that GluA4 subunit confers a minimal mechanism for activity-dependent AMPA-receptor regulation to facilitate plasticity during early development of glutamatergic synapses.

Glutamatergic synapses in particular can be viewed as one of the most complex subcellular specializations in the entire body.” To grapple with these complexities, the company is developing first ...

Commenting on the Spinogenix glaucoma program, and his addition to the Company's SAB, Dr. Weinreb noted, "Glaucoma-related ...

The key questions focus on the cellular and molecular mechanisms that link electrical activity to changes in the structure and function of immature synapses and how these are regulated during ...

Richard Lounsbery Award recipient, will present the 2024 Lounsbery Lecture on "Neuron-glial Interactions in Health and ...

A wealth of data from histological, imaging, genetic and other studies implicate a loss of glutamatergic synapses in frontal cortex and other regions as a primary feature of schizophrenia ...

SPG302 is a clinical stage, orally administered small molecule therapeutic with the unique ability to rapidly regenerate glutamatergic synapses. These synapses, a key feature of retinal circuitry ...